Sai Parenterals profit and loss

Latest FY26

Revenue: ₹381cr
EBITDA: ₹38.7cr
Net profit: ₹14.3cr
EPS: ₹4.36

₹ crore except per share

Tap a line for its trend	FY26Mar 2026

Expenses
	381
	8.5
	390
	238
	4.1
	29.3
	18.4
	16.9
	70.8
	378
	38.7
	21.8
Profit
	11.9
	11.9
	4.9
	−7.3
	−2.3
	14.3
	14.3
	0.1
	14.4
Per share
	₹4.36
	₹4.36
Other comprehensive income — detail
	0.1
	0.1
Per share — as-filed variants
	₹4.36
	₹4.36
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	139
	36.4%
Adjusted (ex-exceptional items) — derived
	11.9
	14.3
	₹4.36

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SAIPARENT₹484.05

Sai Parenterals Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersINDOCO PANACEABIO HIKAL WINDLAS HESTERBIO DCAL SYNCOMF SOLARAMcap ₹2,139 Cr

View

	In ₹ Crore except Per Share 12 Months Ending	FY26 31/03/2026
	Revenue from Operations	381.0
	Other Income	8.5
	Total Income	389.5
	Expenses
	+ Cost of Materials Consumed	238.1
	+ Changes in Inventories	4.1
	+ Employee Benefit Expense	29.3
	+ Finance Costs	18.4
	+ Depreciation & Amortisation	16.9
	+ Other Expenses	70.8
	Total Expenses	377.6
	EBITDA	38.7
	EBIT	21.8
	Profit
	PBT before Exceptional Items	11.9
	Pretax Income	11.9
	+ Current Tax	4.9
	+ Deferred Tax	-7.3
	Tax Expense	-2.3
	Net Income	14.3
	+ Net Income — Continuing Ops	14.3
	+ Other Comprehensive Income	0.1
	Total Comprehensive Income	14.4
	Per Share
	Basic EPS	4.36
	Diluted EPS	4.36
	Other Comprehensive Income — detail
	+ Other Comprehensive Income	0.1
	+ Items NOT to be Reclassified to P&L	0.1
	Per Share — as-filed variants
	Basic EPS — Continuing Operations	4.36
	Diluted EPS — Continuing Operations	4.36
	Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
	Gross Profit	138.8
	Gross Margin %	36.42
	Adjusted (ex-Exceptional Items) — derived
	Pretax Income (Adjusted, as filed)	11.9
	Net Income Adj (tax-effected)	14.3
	EPS Adj	4.36
	Other Filed Concepts — mapped but not yet placed in the schedule
	Face Value	5.00
	Paid Up Equity Capital	22.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.